$AVAH earnings report

Aveanna Q3 2026 revenue rose 11.8% to $695.5 million and Adjusted EBITDA rose 25.0% to $100.1 million; full-year 2026 revenue and Adjusted EBITDA guidance raised. AlphAI read Aveanna Healthcare Holdings's Q3 2026 (three and nine months ended October 3, 2026) filing as strong. 2 quarters are on record below.

Q3 2026 (three and nine months ended October 3, 2026)

AlphAI · Earnings readAVAH · Q3 2026 (three and nine months ended October 3, 2026) · ended 2026-10-03

Aveanna Q3 2026 revenue rose 11.8% to $695.5 million and Adjusted EBITDA rose 25.0% to $100.1 million; full-year 2026 revenue and Adjusted EBITDA guidance raised

✓Strong quarter

Q3 revenue grew 11.8% and operating income grew 55.9% year over year, with net income of $45.5 million against $14.1 million. Nine-month operating cash flow of $157.5 million and free cash flow of $141.2 million were reported. The company raised full-year 2026 revenue and Adjusted EBITDA guidance. Nine-month gross margin fell 1.4 percentage points, which tempers the read.

Revenue
$696M
11.8% y/y
PDS, Q3 2026
$574M
11.6% y/y
Gross margin · GAAP
32.6%
0.0% y/y
EPS · non-GAAP
$0.23
Full year 2026 (year ending January 2, 2027) outlook
greater than $2.695 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Revenue, Q3 2026 (three months)GAAP$695.5M–11.8%
Cost of revenue, excluding depreciation and amortization, Q3 2026GAAP$468.8M–11.8%
Gross margin, Q3 2026GAAP$226.8M–11.8%
Gross margin percentage, Q3 2026GAAP32.6%–0.0%
Branch and regional administrative expenses, Q3 2026GAAP$103.5M–8.5%
Field contribution, Q3 2026non-GAAP$123.3M–14.8%
Field contribution margin, Q3 2026non-GAAP17.7%––
Corporate expenses, Q3 2026GAAP$35.90M–-31.0%
Depreciation and amortization, Q3 2026GAAP$3.17M––
Acquisition-related costs, Q3 2026GAAP$665K––
Operating income, Q3 2026GAAP$83.56M–55.9%
Operating income as a percentage of revenue, Q3 2026GAAP12.0%––
Interest expense, Q3 2026GAAP−$27.09M––
Other income (expense), Q3 2026GAAP$7.94M––
Income before income taxes, Q3 2026GAAP$64.78M––
Income tax (expense) benefit, Q3 2026GAAP−$19.33M––
Net income, Q3 2026GAAP$45.5M––
Net income per diluted share, Q3 2026GAAP$0.20––
Adjusted net income, Q3 2026non-GAAP$52.65M––
Adjusted net income per diluted share, Q3 2026non-GAAP$0.23––
EBITDA, Q3 2026non-GAAP$94.66M––
Adjusted EBITDA, Q3 2026non-GAAP$100.1M–25.0%
Adjusted EBITDA as a percentage of revenue, Q3 2026non-GAAP14.4%––
Revenue, nine months ended October 3, 2026GAAP$2.01B–13.7%
Cost of revenue, excluding depreciation and amortization, nine monthsGAAP$1.36B–16.2%
Gross margin, nine monthsGAAP$650.7M–9.0%
Gross margin percentage, nine monthsGAAP32.3%–-1.4%
Branch and regional administrative expenses, nine monthsGAAP$296.3M–7.0%
Field contribution, nine monthsnon-GAAP$354.4M–10.6%
Field contribution margin, nine monthsnon-GAAP17.6%––
Corporate expenses, nine monthsGAAP$104.1M–-16.0%
Operating income, nine monthsGAAP$232.9M–25.6%
Operating income as a percentage of revenue, nine monthsGAAP11.6%––
Acquisition-related costs, nine monthsGAAP$8.16M––
Interest expense, nine monthsGAAP−$84.02M––
Income before income taxes, nine monthsGAAP$166.2M––
Income tax expense, nine monthsGAAP−$38.83M––
Net income, nine monthsGAAP$127.4M––
Net income per diluted share, nine monthsGAAP$0.57––
Adjusted net income, nine monthsnon-GAAP$142.6M––
Adjusted net income per diluted share, nine monthsnon-GAAP$0.63––
EBITDA, nine monthsnon-GAAP$256.0M––
Adjusted EBITDA, nine monthsnon-GAAP$279.9M–18.7%
Adjusted EBITDA as a percentage of revenue, nine monthsnon-GAAP13.9%––
Net cash provided by operating activities, nine monthsGAAP$157.5M––
Free cash flow, nine monthsnon-GAAP$141.2M––

Segments

SegmentRevenueq/qy/y
PDS, Q3 2026Filing attributes a $59.8 million increase in PDS segment revenue to the consolidated revenue increase. PDS hours were 13,023 thousand, up 10.2%. Revenue rate was $44.09, up 1.4%. Gross margin was 28.9%, down 0.1 percentage points.$574.2M–11.6%
HHH, Q3 2026Filing attributes a $9.7 million increase in HHH segment revenue to the consolidated revenue increase. Home health total admissions were 11.6 thousand, up 19.6%. Episodic mix was 80.2%, up 2.9%. Revenue per completed episode was $3,199, down 0.5%. Gross margin was 53.3%, unchanged.$72.15M–15.6%
MS, Q3 2026Filing attributes a $4.1 million increase in MS segment revenue to the consolidated revenue increase. Unique patients served were 98, up 7.7%. Revenue rate was $501.87, up 1.4%. Gross margin was 45.2%, up 0.2 percentage points.$49.18M–9.1%
PDS, nine months ended October 3, 2026Filing attributes a $203.4 million increase in PDS segment revenue to the nine-month consolidated revenue increase. Hours were 37,608 thousand, up 11.4%. Spread rate was $12.63, down 3.9%. Gross margin was 28.6%, down 1.7 percentage points.$1.66B–13.9%
HHH, nine months ended October 3, 2026Filing attributes a $28.5 million increase in HHH segment revenue to the nine-month consolidated revenue increase. Home health total admissions were 33.1 thousand, up 13.4%. Episodic mix was 80.7%, up 4.3%. Gross margin was 53.6%, down 0.6 percentage points.$207.8M–15.9%
MS, nine months ended October 3, 2026Filing attributes an $11.4 million increase in MS segment revenue to the nine-month consolidated revenue increase. Unique patients served were 286, up 5.5%. Spread rate was $224.22, up 4.7%. Gross margin was 45.0%, up 0.6 percentage points.$142.4M–8.7%

Full year 2026 (year ending January 2, 2027) outlook

  • Revenuegreater than $2.695 billion
  • NoteAdjusted EBITDA: greater than $374 million
  • NoteFiling states revenue guidance was increased from greater than $2.68 billion, and Adjusted EBITDA guidance was increased from greater than $365 million
  • NoteNet income guidance not provided. Company states this is consistent with prior practice due to volatility of certain inputs, including future fair value adjustments associated with interest rate caps

What drove it

  • Filing attributes the Q3 revenue increase of $73.6 million to a $59.8 million increase in PDS, a $9.7 million increase in HHH and a $4.1 million increase in MS
  • Filing attributes the nine-month revenue increase of $243.2 million to a $203.4 million increase in PDS, a $28.5 million increase in HHH and an $11.4 million increase in MS
  • CEO attributes revenue and Adjusted EBITDA growth to strong organic growth across all three business segments, and cites the continued success of its Preferred Payor and Government Affairs strategies. This is the company's explanation
  • Corporate expenses fell $16,099 thousand in Q3 (-31.0%) and $19,894 thousand in nine months (-16.0%) per the filing's key performance table; the filing does not state a cause for this change
  • Interest expense declined to $(27,085) thousand in Q3 from $(35,127) thousand, and to $(84,019) thousand in nine months from $(107,465) thousand; the filing does not state a cause
  • Other income (expense) was $7,936 thousand in Q3 against $(3) thousand in the prior-year quarter. The Adjusted EBITDA reconciliation shows an interest rate derivatives adjustment of $(8,107) thousand in Q3, with the footnote stating these items are included in other income (expense)

Concerns

  • Gross margin percentage for nine months fell to 32.3% from 33.7%, a decline of 1.4 percentage points, while cost of revenue grew 16.2% against revenue growth of 13.7%
  • PDS gross margin for nine months fell to 28.6% from 30.3%, and PDS spread rate fell 3.9% to $12.63 from $13.09
  • Income tax expense for nine months rose to $(38,828) thousand from $(21,421) thousand
  • Acquisition-related costs for nine months were $8,165 thousand against $2,331 thousand in the prior year period
  • Filing states legal costs of $0.2 million in Q3 and $2.8 million in nine months to comply with a Department of Justice, Antitrust Division grand jury subpoena related to nurse wages and hiring activities, in connection with a terminated transaction
  • Filing states $3.9 million of accrued legal settlements and related costs for employment litigation with a certain state in both Q3 and nine months, with no such costs in any other period presented
  • Total indebtedness of $1,521.3 million remains substantial relative to cash of $197.8 million; the filing describes the company's interest rate exposure as hedged
  • Company does not provide net income guidance, citing volatility of inputs including future fair value adjustments on interest rate caps

What to watch

  • Whether PDS gross margin stabilizes given the nine-month decline to 28.6% and the Q3 reading of 28.9% against 29.0%
  • Whether full-year revenue exceeds the guidance floor of $2.695 billion and Adjusted EBITDA exceeds $374 million, as the company has guided
  • Trend in HHH episodic admissions and episodic mix, which rose to 80.2% in Q3
  • Progress on the company's stated deleveraging and reduction of net leverage; the filing does not print a net leverage figure
  • Resolution of the Department of Justice subpoena matter and the other legal matters referenced in the filing
  • Level of interest rate derivative valuation adjustments reported in other income (expense) in future periods

Balance sheet and cash flow

  • Cash and cash equivalents at October 3, 2026: $197,843 thousand; at September 27, 2025: $145,866 thousand (end of period, nine-month cash flow table)
  • Cash flow for nine months ended October 3, 2026: operating $157,524 thousand; investing $(188,684) thousand; financing $35,743 thousand
  • Cash flow for nine months ended September 27, 2025: operating $76,137 thousand; investing $(20,349) thousand; financing $5,790 thousand
  • Free cash flow reconciliation, nine months ended October 3, 2026: purchases of property, equipment and software $(7,753) thousand; principal payments of term loans $(6,608) thousand; principal payments of notes payable $(6,204) thousand; settlements with swap counterparties $4,268 thousand
  • Total indebtedness at October 3, 2026: $1,521,329 thousand, comprising 2026 Term Loans $1,315,079 thousand (S + 3.00%) and Securitization Facility $206,250 thousand (S + 2.50%); 2026 Refinancing Revolving Credit Facility shown as a dash (undrawn)
  • Liquidity at October 3, 2026: cash $197.8 million; incremental borrowing capacity of $68.7 million under securitization facility; revolver undrawn with approximately $225.6 million of borrowing capacity; approximately $24.4 million of outstanding letters of credit
  • Interest rate hedges: $520.0 million notional of interest rate caps capping SOFR exposure at 4.00%; $880.0 million notional of interest rate caps capping SOFR exposure at 2.96%

Analysis

Aveanna reported third-quarter 2026 revenue of $695,540 thousand, up 11.8% from $621,942 thousand, with all three segments growing: PDS up 11.6%, HHH up 15.6% and MS up 9.1%. Net income was $45,451 thousand, or $0.20 per diluted share, against $14,064 thousand, or $0.06, in the prior-year quarter. Adjusted EBITDA was $100,086 thousand, up 25.0%, and its margin rose to 14.4% from 12.9%. Operating income rose 55.9% to $83,556 thousand, and operating margin rose to 12.0% from 8.6%. Q3 gross margin was flat at 32.6%, so the operating margin gain came from lower corporate expenses, which fell 31.0% to $35,901 thousand. The filing does not state a cause for that decline.

Nine-month results show a different mix. Revenue rose 13.7% to $2,013,938 thousand and operating income rose 25.6%, but gross margin fell to 32.3% from 33.7%. PDS, the largest segment, drove most of the growth and also the margin decline: its nine-month gross margin fell 1.7 percentage points to 28.6%, and its spread rate fell 3.9%. HHH margins were 53.6% for the nine months, down 0.6 percentage points, while MS margins improved to 45.0%. Field contribution margin for the nine months was 17.6% against 18.1%, which is consistent with the gross margin trend, though Q3 field contribution margin rose to 17.7% from 17.3%.

Operating cash flow for the nine months was $157,524 thousand, against $76,137 thousand, and free cash flow was $141,227 thousand. Cash rose to $197,843 thousand. Total indebtedness was $1,521,329 thousand, made up of $1,315,079 thousand of term loans and $206,250 thousand under the securitization facility. The filing reports no share repurchases or dividends. Interest expense fell to $(84,019) thousand for the nine months from $(107,465) thousand, while income tax expense rose to $(38,828) thousand from $(21,421) thousand. Adjusted net income per diluted share was $0.63 for the nine months, against $0.43.

The company raised full-year 2026 guidance: revenue is now greater than $2.695 billion, up from greater than $2.68 billion, and Adjusted EBITDA is now greater than $374 million, up from greater than $365 million. No net income or margin guidance was given. The company says this follows its practice because of the volatility of certain inputs, including future fair value adjustments on interest rate caps. Items to examine include the nine-month gross margin decline, the Department of Justice subpoena costs and related legal matters, and the change in other income (expense), which was $7,936 thousand in Q3 against $(3) thousand a year earlier.

Management, verbatim

Our third quarter and year-to-date results highlight the continued momentum in our Aveanna Strategic Plan and our ability to consistently deliver sustained year-over-year growth.

Jeff Shaner, Chief Executive Officer

Year-to-date, we have generated operating cash flow of $157.5 million and free cash flow of $141.2 million, while continuing to reduce net leverage.

Matt Buckhalter, Chief Financial Officer

Not in the filing

stated, not guessed
  • Prior-year and sequential comparisons for Q3 net income, EBITDA dollar change, and nine-month net income percentage change are not printed
  • No prior-quarter (Q2 2026) figures are printed, so all sequential changes are null
  • Prior-year Q3 and nine-month free cash flow are not printed
  • Standalone Q3 operating cash flow and free cash flow are not printed
  • Net leverage ratio figure is not printed
  • Gross margin, operating expense and tax rate guidance were not provided; net income guidance was not provided
  • Share repurchases and dividends are not reported in the filing
  • Consensus estimates, analyst expectations and share price reaction are not provided in the filing
  • Basis for individual yoy percentage changes on depreciation and amortization, acquisition-related costs, interest expense, other income and income tax is not printed

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readAVAH · Second Quarter 2026 · ended July 4, 2026

AVEANNA HEALTHCARE HOLDINGS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND REVISED 2026 GUIDANCE

✓Solid quarter

Second-quarter revenue increased 13.7%, net income increased to $40.3 million from $27.0 million, and the company increased full-year revenue and Adjusted EBITDA guidance. Gross margin, Field contribution margin, operating-income margin, and Adjusted EBITDA margin declined from the prior-year period.

Revenue
$670M
13.7 % y/y
PDS
$554M
14.0 % y/y
Gross margin · GAAP
32.6 %
-3.2 % y/y
EPS · non-GAAP
$ 0.22
Full fiscal year 2026 (year ending January 2, 2027) outlook
greater than $2.68 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
RevenueGAAP$670.5M–13.7 %
Cost of revenue, excluding depreciation and amortizationGAAP$452.0M–19.3 %
Gross marginGAAP$218.5M–3.7 %
Gross margin percentageGAAP32.6 %–-3.2 %
Branch and regional administrative expensesGAAP$97.08M–7.8 %
Field contributionnon-GAAP$121.4M–0.6 %
Field contribution marginnon-GAAP18.1 %–-2.4 %
Corporate expensesGAAP$34.08M–-1.3 %
Corporate expenses as a percentage of revenueGAAP5.1 %––
Depreciation and amortizationGAAP$2.85M––
Acquisition-related costsGAAP$4.39M––
Other operating expenseGAAP$144––
Operating incomeGAAP$79.98M–-0.1 %
Operating income as a percentage of revenueGAAP11.9 %––
Interest incomeGAAP$1.26M––
Interest expenseGAAP−$27.78M––
Other income (expense)GAAP$3.01M––
Income before income taxesGAAP$56.47M––
Income tax expenseGAAP−$16.18M––
Net incomeGAAP$40.29M––
Net income as a percentage of revenueGAAP6.0%––
Net income per share, basicGAAP$ 0.19––
Net income per share, dilutedGAAP$ 0.18––
Adjusted net incomenon-GAAP$49.55M––
Adjusted net income per diluted sharenon-GAAP$ 0.22––
EBITDAnon-GAAP$85.84M––
Adjusted EBITDAnon-GAAP$95.44M–8.0%
Adjusted EBITDA as a percentage of revenuenon-GAAP14.2%––
Revenue, six-month periodGAAP$1.32B–14.8 %
Gross margin, six-month periodGAAP$424.0M–7.5 %
Gross margin percentage, six-month periodGAAP32.2 %–-2.1 %
Operating income, six-month periodGAAP$149.3M–13.3 %
Operating income as a percentage of revenue, six-month periodGAAP11.3 %––
Net income, six-month periodGAAP$81.95M––
Net income per share, diluted, six-month periodGAAP$ 0.37––
Adjusted net income per diluted share, six-month periodnon-GAAP$ 0.40––
Adjusted EBITDA, six-month periodnon-GAAP$179.8M–15.4%
Adjusted EBITDA as a percentage of revenue, six-month periodnon-GAAP13.6%––

Segments

SegmentRevenueq/qy/y
PDSRevenue increased $67.9 million; hours increased 12.3 % and revenue rate increased 1.7 %.$553.9M–14.0 %
HHHHome health total admissions increased 7.1 %, home health episodic admissions increased 16.4 %, and home health total episodes increased 18.5 %.$69.02M–14.8 %
MSUnique patients served increased 4.4 % and revenue rate increased 5.0 %.$47.53M–9.4 %

Full fiscal year 2026 (year ending January 2, 2027) outlook

  • Revenuegreater than $2.68 billion
  • NoteAdjusted EBITDA of greater than $365 million
  • NoteThe company is not providing guidance on net income at this time due to the volatility of certain required inputs that are not available without unreasonable efforts, including future fair value adjustments associated with its interest rate caps.

What drove it

  • The revenue increase was attributable to a $67.9 million increase in PDS segment revenue, an $8.9 million increase in HHH segment revenue, and a $4.1 million increase in MS segment revenue compared to the second quarter of 2025.
  • PDS hours increased 12.3 %, while the PDS revenue rate increased 1.7 %.
  • HHH home health episodic mix was 81.0 %, compared with 74.5 %.
  • MS revenue rate increased 5.0 % and spread rate increased 4.0 %.
  • Corporate expenses decreased $ (446 ) and were 5.1 % of revenue, compared with 5.9 % of revenue.

Concerns

  • Cost of revenue, excluding depreciation and amortization, increased 19.3 %, faster than revenue growth of 13.7 %.
  • Gross margin percentage declined to 32.6 % from 35.8 %, and Field contribution margin declined to 18.1 % from 20.5 %.
  • PDS gross margin percentage declined to 28.9 % from 32.5 %, as PDS cost of revenue rate increased 7.8 % while PDS revenue rate increased 1.7 %.
  • Operating income decreased -0.1 % to $79,980 despite revenue growth.
  • Total indebtedness was $1,483.4 million as of July 4, 2026.

What to watch

  • Execution against full fiscal year 2026 revenue guidance of greater than $2.68 billion and Adjusted EBITDA guidance of greater than $365 million.
  • Whether PDS revenue rate, cost of revenue rate, and spread rate trends change from $44.62, $31.74, and $12.88, respectively.
  • Whether gross margin percentage and Field contribution margin stabilize after the reported declines.
  • HHH admission, episode, episodic-mix, and revenue-per-completed-episode trends.
  • Cash generation, investing cash use, debt levels, and interest-rate-derivative effects.

Balance sheet and cash flow

  • Cash of $97.2 million as of July 4, 2026.
  • Incremental borrowing capacity of $110.0 million under the securitization facility as of July 4, 2026.
  • The revolver was undrawn, with approximately $225.5 million of borrowing capacity and approximately $24.5 million of outstanding letters of credit.
  • Total indebtedness of $1,483.4 million as of July 4, 2026.
  • 2026 Term Loans: $ 1,318,375 at S + 3.00%.
  • Securitization Facility: $ 165,000 at S + 2.50%.
  • Net cash provided by operating activities was $ 85,277 for the six-month period ended July 4, 2026, compared with $ 42,937 for the six-month period ended June 28, 2025.
  • Free cash flow was $ 75,425 for the six-month period ended July 4, 2026.
  • Net cash used in investing activities was $ (179,924 ) for the six-month period ended July 4, 2026, compared with $ (18,330 ) for the six-month period ended June 28, 2025.
  • Net cash used in financing activities was $ (1,417 ) for the six-month period ended July 4, 2026, compared with $ (8,157 ) for the six-month period ended June 28, 2025.
  • $520.0 million notional amount of interest rate caps cap exposure to SOFR at 4.00%.
  • $880.0 million notional amount of interest rate caps cap exposure to SOFR at 2.96%.

Analysis

Aveanna reported second-quarter revenue of $670.5 million, up 13.7% from the prior-year period. Growth was broad across all three reported segments, led by PDS, which contributed a $67.9 million revenue increase. PDS hours increased 12.3%, HHH total admissions increased 7.1%, and MS unique patients served increased 4.4%, indicating that reported growth included both volume and rate measures across the businesses.

The mix of growth and costs pressured margins. Cost of revenue, excluding depreciation and amortization, increased 19.3%, compared with 13.7% revenue growth. Gross margin increased $7.7 million but gross margin percentage declined to 32.6% from 35.8%. PDS was the principal margin pressure point: its revenue rate increased 1.7% while its cost of revenue rate increased 7.8%, and its spread rate declined 11.1%. HHH and MS also reported lower gross margin percentages.

Operating income was $79,980, essentially unchanged from $80,034 in the prior-year period, while operating-income margin declined to 11.9% from 13.6%. Corporate expenses declined $446 and decreased to 5.1% of revenue from 5.9%, but this did not offset the gross-margin and field-contribution pressure. Net income rose to $40,293 from $27,025, with interest expense declining to $(27,776 ) from $(36,003 ). Adjusted EBITDA increased 8.0% to $95,435, although its margin declined to 14.2% from 15.0%.

Liquidity disclosures show cash of $97.2 million, an undrawn revolver with approximately $225.5 million of borrowing capacity, and $1,483.4 million of total indebtedness as of July 4, 2026. The company reported $85,277 of operating cash flow and $75,425 of free cash flow for the six-month period. Net cash used in investing activities was $ (179,924 ), compared with $ (18,330 ) in the prior-year six-month period.

Management increased full-year 2026 revenue guidance to greater than $2.68 billion from between $2.63 and $2.65 billion and increased Adjusted EBITDA guidance to greater than $365 million from between $338 and $342 million. The guidance increase follows first-half revenue growth of 14.8% and Adjusted EBITDA growth of 15.4%. The central operating issue for the remainder of the year is whether revenue and volume growth can be sustained while addressing the reported compression in gross margin, Field contribution margin, operating-income margin, and Adjusted EBITDA margin.

Management, verbatim

Our second quarter results demonstrate the momentum across Aveanna and our ability to consistently deliver sustained year-over-year growth.

Jeff Shaner, Chief Executive Officer

Given our performance in the first half of the year and confidence in our outlook, we are pleased to raise our 2026 revenue and Adjusted EBITDA guidance.

Jeff Shaner, Chief Executive Officer

Our increased 2026 guidance, including revenue of greater than $2.68 billion and Adjusted EBITDA of greater than $365 million, underscores the strength of our business model and the opportunities ahead as we continue to execute on our strategic initiatives.

Matt Buckhalter, Chief Financial Officer

Not in the filing

stated, not guessed
  • Previous quarterly outlook document was not provided; therefore, no actual-versus-prior-guidance comparisons are included.
  • Prior-quarter figures and quarter-over-quarter changes for reported metrics were not provided.
  • Quarterly operating cash flow and free cash flow were not provided.
  • Capital returns, including share repurchases and dividends, were not reported.
  • Gross margin, operating-expense, and tax-rate guidance were not provided.
  • Full-year 2026 net-income guidance was not provided.
  • Segment operating income was not provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about AVAH earnings dates

When is Aveanna Healthcare Holdings's next earnings date?
AlphAI has no date for AVAH yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.